Abstract： Objective To observe the efficacy and safety of intravitreal injection of Ranibizumab (Lucentis)on exudative age-related macular degeneration(AMD). Methods To analyze retrospectively the clinicaI data of 56 patients with exudative AMD,which was diagnosed by examination of ETDRS charts,color fundus photograph,fluorescein angiography(FFA)or indocyanine green angiography(ICGA)and optical coherence tomography(OCT),were underwent intravitreal injection Lucentis0.5 mg.Before the treatment,the ETDRS charts letter of 56 eyes was 25.1;choroidal neovascularization(CNA)was leaky which examined by FFA and ICGA I the average thickness of retina was 303.45 μm.Ranibizumab injection therapeutic times were 2-8,the average therapeutic times were 3.1.Follow-up time was 6-12 months(mean 8.7 months).Visual acuity(ETDRS charts letter),retinaI thickness,leakage of CNV and operative complications before and after the treatment were analyzed. Results At the end of the followup period,the mean lciter of ETDRS charts was 38.5,increased 13.4 letters(P＜0.01),the ETDRS charts improved 15 or more letters in 22 eyes(39.3%),decreased more than 15 letters in 2 eyes(3.6%);the foveal thickness on OCT images were 303.4 5μm before treatment and 191.35μm after treatment,decreased significantly(P＜0.00);FFA and/or ICGA showed CNV complete closure in 12 eyes(21.4%),partial closure in 33 eyes(58.9%),no change in 9 eyes(16.1%)and new CNV in 1 eye(1.8%);Slight complications after operation disappeared during one week. Conclusion Intravitreal injection of Ranibizumab for exudative AMD was well tolerated,with an improvement in VA,FFA or ICGA,and OCT.